Health PR
Worldwide recognition for GLOBALHealthPR partners
The past few weeks have seen our GLOBALHealthPR partners receiving worldwide recognition for their fantastic work in Health + Wellness PR. Last week, our agency, VIVA! Communications, was thrilled to clinch Australia’s ‘Best Public Health Initiative’ at the pharmaceutical industry’s annual PRIME Awards for our Enhancing Community Immunity Through Pharmacist-led Flu Vaccination campaign in partnership with…
Read MorePharmacy Guild of Australia & VIVA! Communications clinch Australia’s Best Public Health Initiative 2018 at PRIME Awards
Last night (September 20) Team VIVA! celebrated a huge win. Together with the Pharmacy Guild of Australia, we clinched Australia’s‘Best Public Health Initiative 2018’award for our ‘Enhancing ‘community immunity’ through pharmacist-led flu vaccinationcampaign at the pharmaceutical industry’s annual PRIME Awards. Held at The Four Seasons Hotel, Sydney, the event attracted more than 800 of the…
Read MoreGLOBALHealthPR appoints VIVA! Communications ‘Asia-Pacific hub’ & welcomes Spurwing Communications as exclusive Singaporean partner
GLOBALHealthPR, the world’s largest partnership of independent health and science communications agencies, today appointed longstanding Australian partner, VIVA! Communications, ‘regional hub’ for Asia-Pacific. The strategic partnership also welcomed Singapore-based Spurwing Communications to its network today, further strengthening GLOBALHealthPR’s capabilities in the Asia-Pacific (APAC) region. Having earned an enviable reputation for servicing the local, regional and…
Read MoreDoctors encouraging middle-aged Aussie blokes to consider their prostate
Doctors are encouraging middle-aged Aussie blokes to have their prostate checked.Their call coincides with an article published in MJA Insight today (Monday, August 13), citing benign prostatic hyperplasia (BPH) – or a benign enlargement of the prostate – can compromise a man’s quality of life, and his relationships with his partner and family.2 According…
Read MoreSeqirus joins international vaccine venture to develop long-lasting, universal flu vaccine
Seqirus (owned by CSL) has joined an international, non-profit venture dedicated to decoding the immune system to develop a universal flu vaccine that affords long-lasting protection against seasonal and pandemic influenza across demographics and geography. The Human Vaccines Project aims to decode the human immune system to accelerate development of vaccines and immunotherapies against major…
Read More